James A. Jr. Robinson
CIK 1734295 · PEO;CEO/Urovant Sciences, Inc. · last filed 2026-06-24
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$572.6K
Companies
6
Total Filings
27
Lifetime Open-Market Net
$0
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| URGN | Director | 6,000 | $40.88 | $245.3K | $0 | 9 | 2026-06-24 |
| ELDN | Director | 3,430 | $3.40 | $11.7K | $0 | 3 | 2026-01-16 |
| APPLIED GENETIC TECHNOLOGIES CORP (AGTC) Delisted | Director | — | $0.39 | — | $0 | 2 | 2022-12-01 |
| Neos Therapeutics, Inc. (NEOS) Delisted | Director | 0 | $1.15 | $0 | $0 | 4 | 2021-03-19 |
| Urovant Sciences Ltd. (UROV) Delisted | PEO; CEO/Urovant Sciences, Inc | 8,385 | $16.24 | $136.2K | $0 | 5 | 2021-01-12 |
| ALKS | President & COO,Alkermes, Inc. | 6,250 | $50.50 | $315.6K | $0 | 3 | 2019-04-05 |
Recent Filings · Page 2 of 3
27 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-07-28 | URGN | Grant (A) | — | $0 | EDGAR |
| 2023-07-27 | URGN | Grant (A) | — | $0 | EDGAR |
| 2022-12-01 | APPLIED GENETIC TECHNOLOGIES CORP (AGTC) Delisted | Disp (D) | — | $0 | EDGAR |
| 2021-12-02 | APPLIED GENETIC TECHNOLOGIES CORP (AGTC) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-03-31 | — | Disp (D) | −8,385 | $0 | |
| 2021-03-19 | Neos Therapeutics, Inc. (NEOS) Delisted | Disp (D) | −23,453 | $0 | EDGAR |
| 2021-01-12 | Urovant Sciences Ltd. (UROV) Delisted | Tax (F) | −4,095 | -$66.0K | EDGAR |
| 2020-06-11 | Neos Therapeutics, Inc. (NEOS) Delisted | Grant (A) | +23,453 | $0 | EDGAR |
| 2020-03-25 | Urovant Sciences Ltd. (UROV) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-01-14 | Urovant Sciences Ltd. (UROV) Delisted | Grant (A) | +12,480 | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.